14 . 03 .2025
Press release
Galderma successfully placed an inaugural EUR 500 million single tranche Eurobond and new dual tranche CHF 435 million CHF bonds
06 . 03 .2025
Press release
Galderma delivers 2024 record net sales of 4.410 billion USD, up 9.3% year-on-year at constant currency1, and record Core EBITDA of 1.031 billion USD, while preparing to accelerate its growth trajectory into 2025 and beyond
03 . 03 .2025
Press release
AAD 2025: Galderma to present extensive updates from across its dermatology portfolio, demonstrating its category leadership and strong momentum
18 . 02 .2025
Press release
Galderma’s Nemluvio® (nemolizumab) granted marketing authorization in the United Kingdom and Switzerland for moderate-to-severe atopic dermatitis and prurigo nodularis
14 . 02 .2025
Press release
Galderma’s Nemluvio® (nemolizumab) approved in the European Union for moderate-to-severe atopic dermatitis and prurigo nodularis
31 . 01 .2025
Press release
IMCAS 2025: New Galderma phase IIIb data reinforce rapid onset and long-lasting aesthetic improvement with RelabotulinumtoxinA (Relfydess™)
30 . 01 .2025
Press release
Galderma demonstrates Injectable Aesthetics leadership in medication-driven weight loss with new research and first international consensus-based guidelines
23 . 01 .2025
Press release
IMCAS 2025: Galderma’s broad presence and new data on recently launched products Restylane® SHAYPE™ and Relfydess® reaffirm its category leadership
